Bio-Rad Laboratories (BIO.B) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Penumbra (PEN) over the past year, gaining 28.2% versus a gain of 22.2%. Over five years, PEN leads with a +19.3% price change compared with -50.5% for BIO.B. Penumbra is the larger company by market cap ($12.58 billion vs $9.76 billion), about 1.3 times the size.
On valuation, Bio-Rad Laboratories trades at a lower trailing P/E (46.3x vs 78.5x for Penumbra). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | PEN |
|---|---|---|
| Share price | $365.08 | $319.40 |
| Market cap | $9.76B | $12.58B |
| 1-day change | 0.00% | +0.59% |
| YTD return | +17.50% | +2.73% |
| 1-year return | +28.15% | +22.19% |
| 5-year return | -50.54% | +19.29% |
| P/E ratio (TTM) | 46.27 | 78.48 |
| Forward P/E | — | 52.09 |
| EPS (TTM) | $7.89 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $1.40B |
| Revenue growth (YoY) | +0.65% | +17.50% |
| Net income (latest FY) | $759.90M | $177.69M |
| Gross margin | 51.87% | 67.14% |
| Operating margin | 1.83% | 13.48% |
| Net margin | 29.42% | 12.66% |
| 52-week high | $365.08 | $362.41 |
| 52-week low | $244.54 | $221.26 |
| Distance from 52-week high | 0.00% | -11.87% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +13.21% |
| Average volume | 4 | 348.57K |
| Shares outstanding | 5.06M | 39.39M |
| Employees | 7,450 | 4,700 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra trades at a higher earnings multiple (78.5x vs 46.3x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 12.7 cents for Penumbra.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +0.65%).
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Healthcare · Medical Devices · 4,700 employees
BIO.B vs PEN FAQ
Which is bigger, Bio-Rad Laboratories or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.58B compared with $9.76B for Bio-Rad Laboratories (BIO.B).
Which stock has performed better over the past year, BIO.B or PEN?
BIO.B returned +28.15% over the past 12 months, compared with +22.19% for PEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or PEN?
BIO.B has the lower trailing P/E at 46.3, versus 78.5 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bio-Rad Laboratories and Penumbra in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.